Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 243-265

  Urbina, Olatz ^a   Ferrández, Olivia ^a   Espona, Mercè ^a   Salas, Esther ^a   Ferrández, Irene ^b   Grau, Santiago ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Linezolid resistance; Oxazolidinone; Skin and soft tissue infections; Tedizolid; TR 700; TR 701 FA

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPICILLIN; AZITHROMYCIN; CEFACLOR; CEFOTAXIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DA 7158; DALFOPRISTIN; DAPTOMYCIN; DOPAMINE RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; QUINUPRISTIN; RIFAMPICIN; SEROTONIN AGONIST; TEDIZOLID; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABSCESS; ACUTE DISEASE; ANEMIA; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BLOOD PRESSURE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CELLULITIS; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG URINE LEVEL; ENTEROCOCCUS; FATIGUE; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEADACHE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INSOMNIA; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OROPHARYNX PAIN; PAIN; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRURITUS; RASH; REVIEW; RHINORRHEA; SIDE EFFECT; SKIN DEFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; VOMITING; XEROSTOMIA;

LINEZOLID RESISTANCE; OXAZOLIDINONE; SKIN AND SOFT TISSUE INFECTIONS; TEDIZOLID; TR-700; TR-701 FA;

ACUTE DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; HUMANS; ORGANOPHOSPHATES; OXAZOLES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TISSUE DISTRIBUTION;

EID: 84875996687     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S30728     Document Type: Review

References (93)

1. Dong SL, Kelly KD, Oland RC, Holroyd BR, Rowe BH. ED management of cellulitis: a review of five urban centers. Am J Emerg Med. 2001;19(7):535-540.
2. Centers for Disease Control and Prevention (CDC). Soft tissue infections among injection drug users - San Francisco, California, 1996-2000. MMWR Morb Mortal Wkly Rep. 2001;50(19):381-384.
3. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15(9): 1516-1518.
4. Shen HN, Lu CL. Skin and soft tissue infections in hospitalized and critically ill patients: a nationwide population-based study. BMC Infect Dis. 2010;10:151.
5. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 2007;57(1):7-13.
6. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
7. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother. 2009;64(3):441-446.
8. Goering RV, Larsen AR, Skov R, Tenover FC, Anderson KL, Dunman PM. Comparative genomic analysis of European and Middle Eastern community-associated methicillin-resistant Staphylococcus aureus (CC80:ST80-IV) isolates by high-density microarray. Clin Microbiol Infect. 2009;15(8):748-755.
9. Hetem DJ, Westh H, Boye K, Jarløv JO, Bonten MJ, Bootsma MC. Nosocomial transmission of community-associated methicillin-resistant Staphylococcus aureus in Danish Hospitals. J Antimicrob Chemother. 2012;67(7):1775-1780.
10. Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA. 2012;308(1):50-59.
11. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40(1): 135-136.
12. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999;340(7): 493-501.
13. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51(26):565-567.
14. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008;46(5):668-674.
15. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother. 2011;55(8):3684-3690.
16. Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis. 2012; 74(1):54-61.
17. Kehrenberg C, Schwarz S, Jacobsen L, Hansen LH, Vester B. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Mol Microbiol. 2005; 57(4):1064-1073.
18. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother. 2006;50(7):2500-2505.
19. Smith LK, Mankin AS. Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. Antimicrob Agents Chemother. 2008;52(5): 1703-1712.
20. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother. 2008;52(6):2244-2246.
21. Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol. 2007;64(6):1506-1514.
22. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(3):1079-1082.
23. Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother. 2011; 66(5):1057-1060.
24. Miller BA, Gray A, Leblanc TW, Sexton DJ, Martin AR, Slama TG. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis. 2010;50(11):e63-e68.
25. Cubicin® (daptomycin for injection) for intravenous use [prescribing information]. Silver Spring, MD: Food and Drug Administration (FDA); 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021572s039lbl.pdf. Accessed July 7, 2012.
26. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010;50(6):821-825.
27. Trius Therapeutics. Tedizolid phosphate (TR-701) profile [web page on the Internet]. San Diego, CA: Trius Therapeutics; nd. Available from: http://www.triusrx.com/trius-therapeutics-tedizolid-profile.php. Accessed July 7, 2012.
28. Bae SK, Yang SH, Shin KN, Rhee JK, Yoo M, Lee MG. Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats. J Pharm Pharmacol. 2007;59(7):955-963.
29. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138(2):135-142.
30. Colca JR, McDonald WG, Waldon DJ, et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003;278(24):21972-21979.
31. Im WB, Choi SH, Park JY, Finn J, Yoon SH. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem. 2011;46(4):1027-1039.
32. Kim E, Choi S, Im W, Rhee J. Pharmacokinetics of TR-701 (DA-7218), a new oxazolidinone in mice, rats and dogs. Poster presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, IL.
33. Bien P, Prokocimer P, Muñoz KA, Bethune C. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects. Poster presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010, Boston, MA.
34. Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother. 2011;55(7):3453-3460.
35. Muñoz KA, Bien P, Prokocimer P, Bethune C. Effect of food on the pharmacokinetics of torezolid (TR-700) in healthy adult subjects. Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases, May 16-19, 2009, Helsinki, Finland.
36. Dreskin H, Boyea T, Barker J, Fang E, Prokocimer P. An evaluation of the absorption, metabolism, and excretion of orally administered [14C]-TR-701 FA in healthy subjects. Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, IL.
37. Prokocimer P, Bien P, Muñoz KA, Bohn J, Wright R, Bethune C. Human pharmacokinetics of the prodrug TR-701 and TR-700, its active moiety, after multiple oral doses of TR-701, a novel oxazolidinone. Poster presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington DC.
38. Bien P, Muñoz KA, Bohn J, Wright R, Bethune C, Prokocimer P. Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic. Poster presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington DC.
39. Mondick J, Gastonguay MR, Bien P, DeAnda C, Prokocimer P. Population pharmacokinetic modeling of TR-700 in patients with complicated skin and skin structure infections. Poster presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010, Boston, MA.
40. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2011;55(2):583-592.
41. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012;56(5):2627-2634.
42. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents. 2012; 40(1):51-54.
43. Flanagan S, Muñoz KA, Minassian S, et al. Improved pharmacokinetics of the novel oxazolidinone antibiotic tedizolid phosphate compared with linezolid in healthy subjects. Poster presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting, October 20-24, 2012, Hollywood, FL.
44. Flanagan S, Morris D, Boyea T, et al. A phase 1 study of intravenously administered tedizolid phosphate in subjects with advanced renal impairment. Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA.
45. Flanagan S, Boyea T, Dreskin H, et al. A phase 1 study of orally administered tedizolid phosphate in subjects with moderate or severe hepatic impairment. Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA.
46. Dreskin H, Muñoz KA, Fang E, et al. Safety and pharmacokinetics of single oral administration of tedizolid phosphate in healthy elderly subjects and adult control subjects. Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA.
47. Dreskin H, Muñoz KA, Bradley J, et al. Safety and pharmacokinetics after single oral and IV administration of tedizolid phosphate in adolescent patients. Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA.
48. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother. 2010;54(5):2063-2069.
49. Betriu C, Morales G, Rodríguez-Avial I, et al. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother. 2010;54(5):2212-2215.
50. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother. 2009;53(8):3236-3239.
51. Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008;52(12):4442-4447.
52. Rodríguez-Avial I, Culebras E, Betriu C, Morales G, Pena I, Picazo JJ. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother. 2012;67(1):167-169.
53. Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J Antimicrob Chemother. 2009;63(4):716-720.
54. Yum JH, Choi SH, Yong D, et al. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob Agents Chemother. 2010;54(12):5381-5386.
55. Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(9):4608-4613.
56. Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother. 2012;56(9):4713-4717.
57. Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother. 2009;63(4): 713-715.
58. Vera-Cabrera L, Gonzalez E, Rendon A, et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother. Sep 2006;50(9): 3170-3172.
59. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet. 2001;357(9263):1179.
60. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358(9277):207-208.
61. Locke JB, Hilgers M, Shaw KJ. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother. 2009;53(12):5275-5278.
62. Locke JB, Morales G, Hilgers M, et al. Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrob Agents Chemother. 2010;54(12):5352-5355.
63. Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother. 2010;54(12):5337-5343.
64. Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother. 2009;53(12):5265-5274.
65. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother. 2009;64(5):1035-1043.
66. Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother. 2011;55(11):5300-5305.
67. Keel RA, Tessier PR, Crandon JL, Nicolau DP. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother. 2012;56(8):4403-4407.
68. Vera-Cabrera L, Espinoza-González NA, Welsh O, Ocampo-Candiani J, Castro-Garza J. Activity of novel oxazolidinones against Nocardia brasiliensis growing within THP-1 macrophages. J Antimicrob Chemother. 2009;64(5):1013-1017.
69. Espinoza-González NA, Welsh O, Ocampo-Candiani J, et al. Evaluation of the Combined Therapy of DA-7218, a New Oxazolidinone, and Trimethoprim/Sulfamethoxazole in the Treatment of Experimental Actinomycetoma by Nocardia brasiliensis. Curr Drug Deliv. May 24, 2010.
70. Espinoza-González NA, Welsh O, de Torres NW, et al. Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis. Molecules. 2008;13(1):31-40.
71. Yamaki J, Synold T, Wong-Beringer A. Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins. Antimicrob Agents Chemother. 2011;55(9):4432-4435.
72. Trius Therapeutics. TR-701 FA vs Linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI). In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 9, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01170221?term=tedizolid&rank=4.NLMidentifier:NCT01170221. Accessed July 7, 2012.
73. Trius Therapeutics. Phase 3 clinical results: TR-701 posters and publications [web page on the Internet]. San Diego, CA: Trius Therapeutics; nd. Available from: http://www.triusrx.com/trius-therapeutics-tedizolid-results.php. Accessed July 7, 2012.
74. De Anda C, Fang E, Das A, Morillo MC, Prokocimer P. Comparison of tedizolid phosphate and linezolid in investigator's assessment of clinical response in patients with cellulitis in United States and Europe from a phase 3 ABSSSI study. Poster presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases, March 31-April 3, 2012, London, UK.
75. Trius Therapeutics. TR-701 FA vs linezolid for the treatment of acute bacterial skin and skin structure infections. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2011 [updated August 1, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01421511?term=tedizolid&rank=14.NLMidentifier:NCT01421511. Accessed January 10, 2013.
76. Bien P, Prokocimer P, Muñoz KA, Bohn J. The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic. Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases, May 16-19, 2009, Helsinki, Finland.
77. Bradley J, Arrieta A, Capparelli E, et al. A phase 1, open-label, multi-center, single-dose, pharmacokinetic, safety and tolerance study of oral tedizolid phosphate in 12 to 17 year old patients. Poster presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases, March 31-April 3, 2012, London, UK.
78. Muñoz KA, Bien P, Prokocimer P. Assessment of the venous tolerability of torezolid phosphate infused via a peripheral catheter: a novel approach. Poster presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, May 7-10, 2011, Milan, Italy.
79. Trius Therapeutics. A phase 2 safety and exploratory skin lesion measurement of TR-701 FA study. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2012 [updated September 5, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01519778?term=tedizolid&rank=10.NLMidentifier:NCT01519778. Accessed July 7, 2012.
80. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723-2726.
81. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2):159-168.
82. Zyvox® (linezolid for injection, tablets, for oral suspension) [package insert]. New York, NY: Pfizer; 2012. Available from: http://www.pfizer.com/files/products/uspi_zyvox.pdf. Accessed July 7, 2012.
83. Kim D, Chung H, Choi S, Im W, Rhee J. Single and repeated-dose toxicity of TR-701 (DA-7218) in rodents. Poster presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, IL.
84. Prokocimer P, Bien P, Muñoz A, Aster R. Hematologic effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects. Poster presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington DC.
85. Bien P, Prokocimer P, Muñoz KA, Bohn J. The safety of 21-day multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic. Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases, May 16-19, 2009, Helsinki, Finland.
86. Javaheri M, Khurana RN, O'hearn TM, Lai MM, Sadun AA. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol. 2007;91(1):111-115.
87. Frippiat F, Derue G. Causal relationship between neuropathy and prolonged linezolid use. Clin Infect Dis. 2004;39(3):439.
88. Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis. 2003;37(10):1389-1391.
89. Trius Therapeutics. A phase 1, open-label, 10 day safety study. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2012 [updated December 5, 2012]. Available from: http://clinicaltrials.gov/ct2/show?term=tedizolid&rank=11.NLMidentifier:NCT01623401. Accessed July 7, 2012.
90. FDA. Zyvox (linezolid): drug safety communication: serious CNS reactions possible when given to patients taking certain psychiatric medications [web page on the Internet]. Silver Spring, MD: FDA, nd [updated October 21, 2011]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265479.htm. Accessed July 7, 2012.
91. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011;1241:48-70.
92. Flanagan S, Minassian S, Fang E, et al. Lack of MAO inhibition by tedizolid phosphate in clinical and nonclinical studies. Poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA.
93. Bae SK, Chung WS, Kim EJ, et al. Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother. 2004;48(2):659-662